Posts Tagged: Colorectal Cancer
23/04/2019
Successful start of the clinical validation study of COLODETECT® test
23rd, April 2019 Protein Alternatives S.L. (PROALT) has begun the clinical validation study of its blood-based diagnostic test for colorectal cancer in Luminex® and ELISA-based formats. COLODETECT® test is based…
08/06/2016
Presentation of ColoDetect project in the European Commission booth at BIO 2016
10th, June 2016 PROALT has been selected by Enterprise Europe Network (EEN) as a successfully funded company and invited to present its ColoDetect project in the European Commission’s booth #5977…
01/04/2016
PROALT has launched ColoDetect website to disseminate project results
1st, April 2016 ColoDetect project announces the launch of its website. ColoDetect is a project funded by the European Union through the H2020 SME Instrument Phase 2 and developed by…
01/10/2015
PROALT receives H2020-SME Instrument funding to develop ColoDetect project
October 1st, 2015 COLODETECT, a proposal submitted by the Spanish biotechnology company PROALT, has been selected to receive EU funding from H2020 SME Instrument. In total, the Commission received 580...
05/06/2015
ColoDetect project: featured news in ‘El Mundo’, one of the main national newspapers
May 6th, 2015 The ‘Innovators’ supplement of the ‘El Mundo’ newspaper, one of the most widely distributed journals in Spain, has interviewed Dr Juan Ignacio Imbaud, R&D Director of the…
10/01/2015
ColoDetect project: selected to receive funding from the EU Horizon 2020 Programme
January 10th, 2015 Protein Alternatives’ project proposal named ‘ColoDetect – Development of a novel blood-based diagnostic test for colorectal cancer’ has been selected to receive funding from the EU Framework…
10/10/2014
PROALT has been selected finalist in ‘The South Summit 2014’ startups competition
October 10th, 2014 Protein Alternatives has been finalist in ‘The South Summit’ 2014. The company was selected within the 100 finalists from more than 3000 startups from Southern Europe and…